Results of Operations and Financial Condition. On August 5, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the second quarter ended June 30, 2026, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Costs Associated with Exit or Disposal Activities. On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline. At the time of the Original Report, the Company was not able to make a good faith estimate of the costs it would incur in connection with the Plan. The Comp…

Costs Associated with Exit or Disposal Activities. On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”). The Plan was approved as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline, following a comprehensive strategic review and scientific diligence of the…

The filing is about an equity plan amendment, not a management change.

Results of Operations and Financial Condition. On May 6, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the first quarter ended March 31, 2026, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Results of Operations and Financial Condition. On February 26, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Entry Into a Material Definitive Agreement. On January 23, 2026 (the “ Closing Date ”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), entered into a Loan Agreement (the “ Loan Agreement ”), by and among BioCryst, as borrower, the guarantors from time to time party thereto, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as the Blackstone representatives thereunder, the lenders from time to time party thereto and Wilmington Trust…

Completion of Acquisition or Disposition of Assets. On the Closing Date, BioCryst completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the “ Merger Agreement ”), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst (“ Merger Sub ”), and Astria Therapeutics, Inc., a Delaware corporation (“ Astria ”). On the Closing Date, Merger Sub merged with and into Astria (the “ Merger ”), with A…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

member of Compensation and Science Committees — Jill C. Milne, Ph.D.: Dr. Jill C. Milne was appointed to the Compensation and Science Committees following a merger.

Results of Operations and Financial Condition. On January 12, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) announcing, among other things, preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year ended December 31, 2025. The Company also provided guidance for full year 2026 ORLADEYO net revenue, total revenue, and operating expenses. The Press Release also referenced a previously announced, upcoming w…

Chair of the Board — Nancy J. Hutson, Ph.D.: Dr. Nancy J. Hutson is retiring from the Board of Directors with a named successor, Vincent J. Milano.

Other Events. On December 3, 2025, BioCryst Pharmaceuticals, Inc. (“BioCryst”) issued a press release announcing early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to its previously announced proposed acquisition (the “Merger”) of Astria Therapeutics, Inc. (“Astria”). A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Termination of the waiting per…

Results of Operations and Financial Condition. On November 3, 2025, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the third quarter ended September 30, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Other Events. On October 8, 2025, BioCryst paid off in full and terminated that certain Loan Agreement, dated as of April 17, 2023, among BioCryst, the other guarantors from time to time party thereto, BioPharma Credit PLC, as collateral agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, as lenders (as amended, restated, amended and restated, supplemented or otherwise modified from time to time). On October 14, 2025, BioCryst and Astria issued a joint press re…

Director — Jill C. Milne, Ph.D.: Dr. Jill C. Milne was elected to the BioCryst Board as part of an enlargement of the board.

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On October 14, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst (“ Merger Sub ”), and Astria Therapeutics, Inc., a Delaware corporation (“ Astria ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the co…

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by BioCryst under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland amended and restated that certain IP Licence Agreement by and between the Company and BioCryst Ireland, dated as of May 13, 2021 (such amended and restated agreement, the “ Amended and Restated IP Licence Agreement ”). Pursuant to the Amended and Restated IP Licence Agreement, the Company granted to BioCryst Ireland an exclusive license under certain patents, sol…

Chief Research and Development Officer — Dr. Helen Thackray: Dr. Thackray resigned from her role as Chief Research and Development Officer to pursue new opportunities.

Results of Operations and Financial Condition. On August 4, 2025, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the second quarter ended June 30, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

President and Chief Executive Officer — Jon Stonehouse: Jon Stonehouse is retiring as President and CEO, with Charlie Gayer appointed as his successor.

Chief Financial Officer, Principal Accounting Officer, Head of Corporate Development — Babar Ghias: The company hired a new CFO and expanded his role to include Principal Accounting Officer and Head of Corporate Development.

Entry into a Material Definitive Agreement. On June 27, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ” or the “ Company ”), and BioCryst Ireland Limited (“ BioCryst Ireland ”), a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Company, entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with Neopharmed Gentili S.p.A., a corporation organized under the laws of Italy (the “ Purchaser ”). Under the t…

Director — George B. Abercrombie: Mr. Abercrombie retired from the Board of Directors after more than 13 years of service.